Worrisome findings as the US Food and Drug Administration finishes visiting never-before-inspected drug manufacturing facilities around the world helped drive a surge in warning letters in the fiscal year that ended 30 September, an agency official said.
These letters went to firms making over-the-counter drug products and targeted inadequate testing of raw materials and components, and failure to test finished products
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?